Happy , almost new year 2025 to all Hello Onc site readers.
One more trading day, to close out any rax loss selling.
The 25%++ improvement since recent bottom indicates, the smart $$ is staying in.
However , things being things; no doubt some tax loss selling gravity.
Looking at the calendar, there is the 31st still, but historically little trading then. Great opportunity to pick up some discount shares.
My very short term look. I see normality to markets in general restoring on the 6th.
Thst being a week beige the JP Morgan health care conference Jan 13th, 2:30 pm pacific time.
Not certain, but I think the markets will be closed by then.
needless to say, interesting back- back events. Being early & late January.
One business oriented, the other new clinical efficacy results on the Goblet ( with Roche) , anal trial.
As I look at 2025 & back @ 2024. I certainly hope on a personal level better things ahead.
This was a terrible year for me. I'm not talking finances. As I said, my ny resolution is to get better.
beyind that, a wish...not a resolution.
My 2025 wish, for this site.
That the name calling stop. This is a chat site to discuss oncolytics biotech.
As a company , its product & hopeful development as a cancer therapy.
There is lots of direct & relative comparables posted in here, to have intelligent dialog.
Sadley a few on here, have very obvious negative agendas.
i do feel sorry for those, as in my firm beliefs ONC will get Pela to market.
obviously not in the next few months.
What they must & will do, within the next few months is demonstrate the $$$ willingness of outside institutions/ private investment pools/ pharma companies to be part of oncs future.
i have no idea what that will look like. We have discussed the buyout options quite a bit. That is my presence.
parterships?
A dilutive large scale share purchase is possible, Not needed or likely.
A complex restructuring, involving a third party, possible. Would require shaeholder approval & would need to be acretitive for shareholders ( profitable).
A few uneducated in finance indicate bankruptcy. Not possible. They have ample cash, no debt. so, put that one & the R/ S to bed.
As notable said very well. Onc is a late stage Jr. biotech. With manufacturing approvals & capabilities. Proven various clinical efficacious results & has the on going support & collaboration with global entities.
Niw, time to bring the ball across the line.
All the best to everyone in 2025.